Inflammasome Therapeutics to Collaborate with Sean M. Healey & AMG Center for ALS on a new treatment for Amyotrophic Lateral Sclerosis (ALS)
Trial to Evaluate Inflammasome’s Kamuvudine-9 (K9) in Individuals with ALS
Excerpt from the Press Release:
NEWTON, Mass.–(BUSINESS WIRE)–Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and neurological conditions, announced the company has signed a contract with The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital to design a new Healey ALS MyMatch trial evaluating oral Kamuvudine-9 (K9) in individuals with amyotrophic lateral sclerosis (ALS).
The collaboration is in response to the Healey & AMG Center’s Spring 2025 call for applications for the ALS MyMatch program. Inflammasome Therapeutics is one of the first companies selected for inclusion in ALS MyMatch, according to the Center.
“We are honored to be selected and delighted to enter this collaboration with the Healey & AMG Center at Mass General,” said Paul Ashton, Ph.D. co-founder and CEO of Inflammasome Therapeutics. “We are developing a series of compounds targeting neuroinflammation, a disease process that characterizes such diverse diseases as ALS, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and macular degeneration, and two of these drugs are already in clinical trials and showing great promise.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?